AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
benzoyl peroxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 328 | 94-36-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A peroxide derivative that has been used topically for BURNS and as a dermatologic agent in the treatment of ACNE and POISON IVY DERMATITIS. It is used also as a bleach in the food industry.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,MAP3K1,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MARK4,MELK,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK | 42 | |||
| kinase-selectivity-class | ACVR2B,AXL,DYRK1B,EIF2AK3,ERBB2,GRK2,PDK4,STK33,TTK | 9 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 26, 1984 | FDA | VALEANT INTL |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Swelling face | 49.48 | 25.22 | 23 | 1135 | 81329 | 90545960 |
| Erythema | 36.15 | 25.22 | 27 | 1131 | 229219 | 90398070 |
| Dry skin | 35.97 | 25.22 | 19 | 1139 | 88054 | 90539235 |
| Eye swelling | 33.52 | 25.22 | 13 | 1145 | 29373 | 90597916 |
| Cerebral ischaemia | 32.38 | 25.22 | 9 | 1149 | 7187 | 90620102 |
| Hidradenitis | 31.84 | 25.22 | 8 | 1150 | 4339 | 90622950 |
| Acne | 30.36 | 25.22 | 12 | 1146 | 28495 | 90598794 |
| Embolism | 29.93 | 25.22 | 9 | 1149 | 9472 | 90617817 |
| Posterior reversible encephalopathy syndrome | 25.89 | 25.22 | 10 | 1148 | 22329 | 90604960 |
| Bladder discomfort | 25.71 | 25.22 | 5 | 1153 | 841 | 90626448 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Swelling face | 56.31 | 25.52 | 27 | 1537 | 92294 | 110495441 |
| Erythema | 35.90 | 25.52 | 31 | 1533 | 291416 | 110296319 |
| Pneumomediastinum | 34.65 | 25.52 | 9 | 1555 | 5027 | 110582708 |
| Eye swelling | 34.12 | 25.52 | 14 | 1550 | 33034 | 110554701 |
| Acne | 33.93 | 25.52 | 14 | 1550 | 33506 | 110554229 |
| Dystonia | 33.87 | 25.52 | 13 | 1551 | 25792 | 110561943 |
| Dry skin | 28.07 | 25.52 | 18 | 1546 | 107635 | 110480100 |
| Cerebral ischaemia | 26.86 | 25.52 | 9 | 1555 | 12095 | 110575640 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D10AE01 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Peroxides |
| ATC | D10AE51 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Peroxides |
| MeSH PA | D003879 | Dermatologic Agents |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Atopic dermatitis | indication | 24079001 | DOID:3310 |
| Contact dermatitis | indication | 40275004 | DOID:2773 |
| Seborrheic dermatitis | indication | 50563003 | DOID:8741 |
| Granuloma annulare | indication | 65508009 | DOID:3777 |
| Acne vulgaris | indication | 88616000 | |
| Pruritus ani | indication | 90446007 | |
| Pruritus of genital organs | indication | 267802000 | |
| Eruption of skin | indication | 271807003 | DOID:0050486 |
| Infection of skin AND/OR subcutaneous tissue | contraindication | 19824006 | |
| Crohn's disease | contraindication | 34000006 | |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Photosensitivity | contraindication | 90128006 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Condyloma acuminatum | contraindication | 240542006 | DOID:11168 |
| Telangiectasia disorder | contraindication | 247479008 | |
| Skin irritation | contraindication | 367466007 | |
| Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
| Pseudomembranous enterocolitis | contraindication | 397683000 | |
| Atrophoderma | contraindication | 399979006 | |
| Erythroderma | contraindication | 399992009 | |
| Peripheral vascular disease | contraindication | 400047006 | |
| Blister | contraindication | 417237009 | |
| Denuded skin | contraindication | 418242004 | |
| Inflammatory dermatosis | contraindication | 703938007 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.1%;2.5% | EPIDUO | GALDERMA LABS LP | N022320 | Dec. 8, 2008 | DISCN | GEL | TOPICAL | 8071644 | July 18, 2027 | TREATMENT OF ACNE |
| 0.1%;2.5% | EPIDUO | GALDERMA LABS LP | N022320 | Dec. 8, 2008 | DISCN | GEL | TOPICAL | 8080537 | July 18, 2027 | TREATMENT OF ACNE |
| 0.1%;2.5% | EPIDUO | GALDERMA LABS LP | N022320 | Dec. 8, 2008 | DISCN | GEL | TOPICAL | 8129362 | July 18, 2027 | TREATMENT OF ACNE |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 9868103 | Aug. 8, 2028 | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER |
| 3%;0.1% | TWYNEO | MAYNE PHARMA | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 9868103 | Aug. 8, 2028 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER |
| 2.5%;EQ 1.2% BASE | ACANYA | BAUSCH | N050819 | Oct. 23, 2008 | RX | GEL | TOPICAL | 10220049 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER |
| 2.5%;EQ 1.2% BASE | ACANYA | BAUSCH | N050819 | Oct. 23, 2008 | RX | GEL | TOPICAL | 10624918 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER |
| 2.5%;EQ 1.2% BASE | ACANYA | BAUSCH | N050819 | Oct. 23, 2008 | RX | GEL | TOPICAL | 8663699 | June 3, 2029 | TREATMENT OF ACNE |
| 2.5%;EQ 1.2% BASE | ACANYA | BAUSCH | N050819 | Oct. 23, 2008 | RX | GEL | TOPICAL | 8895070 | June 3, 2029 | TREATMENT OF ACNE |
| 3.75%;EQ 1.2% BASE | ONEXTON | BAUSCH | N050819 | Nov. 24, 2014 | RX | GEL | TOPICAL | 10137142 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER |
| 3.75%;EQ 1.2% BASE | ONEXTON | BAUSCH | N050819 | Nov. 24, 2014 | RX | GEL | TOPICAL | 10220049 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER |
| 3.75%;EQ 1.2% BASE | ONEXTON | BAUSCH | N050819 | Nov. 24, 2014 | RX | GEL | TOPICAL | 9504704 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS |
| 3.75%;EQ 1.2% BASE | ONEXTON | BAUSCH | N050819 | Nov. 24, 2014 | RX | GEL | TOPICAL | 9504704 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER |
| 3.75%;EQ 1.2% BASE | ONEXTON | BAUSCH | N050819 | Nov. 24, 2014 | RX | GEL | TOPICAL | 9504704 | June 3, 2029 | TREATMENT OF ACNE |
| 3.75%;EQ 1.2% BASE | ONEXTON | BAUSCH | N050819 | Nov. 24, 2014 | RX | GEL | TOPICAL | 9504704 | June 3, 2029 | TREATMENT OF ACNE VULGARIS |
| 3.75%;EQ 1.2% BASE | ONEXTON | BAUSCH | N050819 | Nov. 24, 2014 | RX | GEL | TOPICAL | 9561208 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 10220049 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 10624918 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 9561208 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| 2.5%;EQ 1.2% BASE | ACANYA | BAUSCH | N050819 | Oct. 23, 2008 | RX | GEL | TOPICAL | 8288434 | Aug. 5, 2029 | TREATMENT OF ACNE |
| 3.75%;EQ 1.2% BASE | ONEXTON | BAUSCH | N050819 | Nov. 24, 2014 | RX | GEL | TOPICAL | 8288434 | Aug. 5, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS |
| 3.75%;EQ 1.2% BASE | ONEXTON | BAUSCH | N050819 | Nov. 24, 2014 | RX | GEL | TOPICAL | 8288434 | Aug. 5, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER |
| 3.75%;EQ 1.2% BASE | ONEXTON | BAUSCH | N050819 | Nov. 24, 2014 | RX | GEL | TOPICAL | 8288434 | Aug. 5, 2029 | TREATMENT OF ACNE |
| 3.75%;EQ 1.2% BASE | ONEXTON | BAUSCH | N050819 | Nov. 24, 2014 | RX | GEL | TOPICAL | 8288434 | Aug. 5, 2029 | TREATMENT OF ACNE VULGARIS |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 8288434 | Aug. 5, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| 3%;0.1% | TWYNEO | MAYNE PHARMA | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 10653899 | Dec. 30, 2030 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER |
| 3%;0.1% | TWYNEO | MAYNE PHARMA | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 12070629 | Dec. 30, 2030 | TOPICAL TREATMENT OF ACNE |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 9687465 | Nov. 27, 2032 | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER |
| 3%;0.1% | TWYNEO | MAYNE PHARMA | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 10420743 | July 12, 2038 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER |
| 3%;0.1% | TWYNEO | MAYNE PHARMA | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 12357602 | July 12, 2038 | TOPICAL TREATMENT OF ACNE |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 10933046 | Feb. 19, 2040 | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 65 YEARS OF AGE AND OLDER |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 10945987 | Feb. 19, 2040 | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 11541026 | Feb. 19, 2040 | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 11865100 | Feb. 19, 2040 | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 65 YEARS OF AGE AND OLDER |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 11877997 | Feb. 19, 2040 | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 11986456 | Feb. 19, 2040 | TOPICAL TREATMENT OF ROSACEA |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 12128059 | July 31, 2040 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 11426378 | Aug. 18, 2040 | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 11628155 | Dec. 27, 2040 | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 12295935 | Dec. 27, 2040 | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER |
| 3%;0.1% | TWYNEO | MAYNE PHARMA | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 12295935 | Dec. 27, 2040 | TOPICAL TREATMENT OF ACNE |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 11389467 | Dec. 28, 2040 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| 5% | EPSOLAY | MAYNE PHARMA | N214510 | April 22, 2022 | RX | CREAM | TOPICAL | 12257348 | May 23, 2041 | TOPICAL TREATMENT OF ROSACEA |
| 3%;0.1% | TWYNEO | MAYNE PHARMA | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 12133919 | May 23, 2041 | TOPICAL TREATMENT OF ACNE |
| 3%;0.1% | TWYNEO | MAYNE PHARMA | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 12257348 | May 23, 2041 | TOPICAL TREATMENT OF ACNE |
| 3%;0.1% | TWYNEO | MAYNE PHARMA | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 12491163 | May 23, 2041 | TOPICAL TREATMENT OF ACNE |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | Oct. 20, 2026 | NEW PRODUCT |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4018562 | VUID |
| N0000146882 | NUI |
| D03093 | KEGG_DRUG |
| 1418 | RXNORM |
| C0005088 | UMLSCUI |
| CHEBI:82405 | CHEBI |
| CHEMBL1200370 | ChEMBL_ID |
| DB09096 | DRUGBANK_ID |
| D001585 | MESH_DESCRIPTOR_UI |
| 7187 | PUBCHEM_CID |
| W9WZN9A0GM | UNII |
| 169 | MMSL |
| 4261 | MMSL |
| 4018562 | VANDF |
| 001955 | NDDF |
| 354053005 | SNOMEDCT_US |
| 91598004 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cabtreo | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0187-0006 | GEL | 31 mg | TOPICAL | NDA | 26 sections |
| ONEXTON | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0187-3050 | GEL | 37.50 mg | TOPICAL | NDA | 26 sections |
| Cetaphil Gentle Clear BPO Acne Cleanser | HUMAN OTC DRUG LABEL | 1 | 0299-4125 | CREAM | 2.60 g | TOPICAL | OTC Monograph Drug | 9 sections |
| Differin Max Strength Acne Foaming BPO Cleanser | HUMAN OTC DRUG LABEL | 1 | 0299-4137 | SOLUTION | 10 g | TOPICAL | OTC Monograph Drug | 9 sections |
| Differin Daily Deep Cleanser with BPO | HUMAN OTC DRUG LABEL | 1 | 0299-4606 | SOLUTION | 5 g | TOPICAL | OTC Monograph Drug | 9 sections |
| Differin 10% BPO Acne Treatment | HUMAN OTC DRUG LABEL | 1 | 0299-4611 | SOLUTION | 10 g | TOPICAL | OTC Monograph Drug | 9 sections |
| Differin Epiduo | HUMAN OTC DRUG LABEL | 2 | 0299-4908 | GEL | 25 mg | TOPICAL | NDA | 15 sections |
| epiduo forte | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0299-5906 | GEL | 25 mg | TOPICAL | NDA | 24 sections |
| TWYNEO | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0299-5945 | CREAM | 30 mg | TOPICAL | NDA | 26 sections |
| PanOxyl | HUMAN OTC DRUG LABEL | 1 | 0316-0227 | CREAM | 58.70 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| PanOxyl | HUMAN OTC DRUG LABEL | 1 | 0316-0227 | CREAM | 58.70 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| PanOxyl | HUMAN OTC DRUG LABEL | 1 | 0316-0228 | CREAM | 100 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| PanOxyl | HUMAN OTC DRUG LABEL | 1 | 0316-0228 | CREAM | 100 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| PanOxyl | HUMAN OTC DRUG LABEL | 1 | 0316-0264 | SOAP | 12.60 g | TOPICAL | OTC Monograph Drug | 14 sections |
| PanOxyl | HUMAN OTC DRUG LABEL | 1 | 0316-0264 | SOAP | 12.60 g | TOPICAL | OTC Monograph Drug | 14 sections |
| PanOxyl Acne Clearing Spot Treatment | HUMAN OTC DRUG LABEL | 1 | 0316-0298 | GEL | 100 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Walgreens Acne Spot Treatment | HUMAN OTC DRUG LABEL | 1 | 0363-0116 | LOTION | 25 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| Acne Cleansing Bar | HUMAN OTC DRUG LABEL | 1 | 0363-0137 | SOAP | 100 mg | TOPICAL | OTC monograph final | 13 sections |
| Acne Treatment | HUMAN OTC DRUG LABEL | 1 | 0363-0229 | GEL | 1 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Walgreens Maximum Strength Tinted Acne Spot Treatment Cream | HUMAN OTC DRUG LABEL | 1 | 0363-0256 | CREAM | 100 mg | TOPICAL | OTC Monograph Drug | 11 sections |
| Walgreens Maximum Strength Acne Gel | HUMAN OTC DRUG LABEL | 1 | 0363-0266 | GEL | 100 mg | TOPICAL | OTC Monograph Drug | 11 sections |
| Walgreens Acne Foaming CleanserAcne Treatment | HUMAN OTC DRUG LABEL | 1 | 0363-0467 | CREAM | 40 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Walgreens Maximum Strength Acne Treatment | HUMAN OTC DRUG LABEL | 1 | 0363-1363 | GEL | 100 mg | TOPICAL | OTC Monograph Drug | 10 sections |
| Walgreens Acne Foaming WashAcne Medication | HUMAN OTC DRUG LABEL | 1 | 0363-1522 | LOTION | 100 mg | TOPICAL | OTC Monograph Drug | 15 sections |
| Foaming Acne Face WashWalgreens | HUMAN OTC DRUG LABEL | 1 | 0363-2181 | CREAM | 10 g | TOPICAL | OTC monograph final | 11 sections |
| Walgreens Creamy Acne Face WashAcne Medication | HUMAN OTC DRUG LABEL | 1 | 0363-2492 | LOTION | 40 mg | TOPICAL | OTC Monograph Drug | 15 sections |
| Foaming Acne Face WashWalgreens | HUMAN OTC DRUG LABEL | 1 | 0363-3181 | CREAM | 10 g | TOPICAL | OTC monograph final | 11 sections |
| Walgreens Acne Control CleanserAcne Medication | HUMAN OTC DRUG LABEL | 1 | 0363-3602 | LOTION | 100 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Walgreens Daily Acne Cleanser- Sensitive Skin Formula | HUMAN OTC DRUG LABEL | 1 | 0363-5602 | LOTION | 50 mg | TOPICAL | OTC Monograph Drug | 15 sections |
| Spot Acne Treatment | HUMAN OTC DRUG LABEL | 1 | 0363-7784 | LOTION | 2.50 g | TOPICAL | OTC monograph final | 7 sections |